Total: 4 |
|
PMID (PMCID) | ||
---|---|---|
20220267 (2855068) |
MIXED_SAMPLE | Infant, Newborn |
Homozygosity for the Mediterranean a-thalassemic deletion (hemoglobin Barts hydrops fetalis). | ||
Al-Allawi NA, Shamdeen MY, Rasheed NS. Ann Saudi Med. 2010;30(2):153-5. |
||
Molecular studies revealed that the fetus had the hemoglobin Barts hydrops fetalis syndrome due to homozygosity for the Mediterranean alpha-thalassemia deletion. | ||
20220267 (2855068) |
MIXED_SAMPLE | Infant, Newborn |
Homozygosity for the Mediterranean a-thalassemic deletion (hemoglobin Barts hydrops fetalis). | ||
Al-Allawi NA, Shamdeen MY, Rasheed NS. Ann Saudi Med. 2010;30(2):153-5. |
||
Hemoglobin Barts hydrops fetalis syndrome is the most severe and generally fatal clinical phenotype of alpha-thalassemia. | ||
11498754 |
FEMALE | Infant |
Successful mismatched sibling cord blood transplant in Hb Bart's disease. | ||
Zhou X, Ha SY, Chan GC, Luk CW, Chan V, Hawkins B, Lam YH, Liang RH, Lau YL. Bone Marrow Transplant. 2001;28(1):105-7. |
||
Ten percent of hemoglobin Bart's was detected 2 months after transplant and this reflects the alpha-thalassemia trait of the donor. | ||
1292309 |
MIXED_SAMPLE | |
Long-term survival of a baby with homozygous alpha-thalassemia-1. | ||
Lam TK, Chan V, Fok TF, Li CK, Feng CS. Acta Haematol. 1992;88(4):198-200. |
||
The girl with hemoglobin Bart's hydrops syndrome, confirmed by gene analysis to be homozygous for alpha-thalassemia-1, survives for 27 months at the time of reporting. |